Brief: Lotus Pharmaceutical Says Its Nintedanib Capsules Has Obtained Tentative Aproval From U.S. FDA
16/01/2023 24:23
Jan 16 (Reuters) - Lotus Pharmaceutical Co Ltd
1795.TW :
* SAYS ITS DRUG NINTEDANIB CAPSULES HAS OBTAINED TENTATIVE
APROVAL
FROM U.S. FDA
Source text for Eikon: ID:nMOP7m1pwv
Further company coverage: 1795.TW
(Reporting by Hong Kong newsroom)
((donny.kwok@thomsonreuters.com; +852 3462 7745;))
Recent news on Lotus Pharmaceutical
See all newsMedia: PTT is said to consider options for Taiwan-listed Lotus Pharma - Bloomberg News
Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
Brief: Lotus Pharmaceutical Says Unit Has Closed Deal In Vietnam
Brief: Fuji Pharma: Marketing Approval For Generic Lenalidomide, The First Collaboration Product With Taiwan's Lotus
Brief: Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership In Southeast Asia And South Korea